glucagon receptor is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-11-07. Where a claim depends on a specific study, the study is described rather than over-claimed.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide of about 39 residues | Backbone derived from a GIP sequence |
| Molecular mass | Approximately 4.7 kDa | Peptide chain plus fatty diacid moiety |
| Receptor targets | GLP-1, GIP, glucagon | Unimolecular triple agonist |
| Typical storage temperature | 2 to 8 degrees Celsius | Protect from light; avoid repeated freeze-thaw |
| Common analytical method | LC-MS/MS | Used for plasma quantification and purity checks |
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
== Production == ANP is synthesized as an inactive preprohormone, encoded by the human NPPA gene located on the short arm of chromosome 1. The NPPA gene is expressed primarily in atrial myocytes and consists of 2 introns and three exons, with translation of this gene yielding a high molecular mass 151 amino acid polypeptide known as preproANP. The preprohormone is activated via post-translational modification that involves cleavage of the 25 amino acid signal sequence to produce proANP (26–151), a 126 amino acid peptide that is the major form of ANP stored in intracellular granules of the atria. Following stimulation of atrial cells, proANP is released and rapidly converted to the 28-amino-acid C-terminal mature ANP (124–151) on the cell surface by the cardiac transmembrane serine protease corin; the remaining N-terminal part is called "NT-proANP" (26–123). ANP is secreted in response to:
== Synthesis == MDP is synthesized according to the following reactions: at first, 10-hydroxydecyl methacrylate is synthesized by reaction of methacrylic acid and 1,10-decanediol. Next, phosphoryl chloride is added to 10-hydroxydecy methacrylate, then, the phosphorus-chlorine bonds in this intermediate are hydrolyzed.
==== Non-opioid receptor genes ==== While opioid receptors have been the most widely studied, a number of other genes have been implicated in OUD. Higher numbers of (CA) repeats flanking the preproenkephalin gene, PENK, have been associated with opiate dependence. There have been mixed results for the MCR2 gene, encoding melanocortin receptor type 2, implicating both protection and risk to heroin addiction. A number of enzymes in the cytochrome P450 family may also play a role in dependence and overdose due to variance in breakdown of opioids and their receptors. There are also multiple potential complications with combining opioids with antidepressants and antiepileptic drugs (both common drugs for chronic pain patients) because of their effects on inducing CYP enzymes. Genotyping of CYP2D6 in particular may play a role in helping patients with individualized treatment for OUD and other drug addictions.
may be read as the average number of infections caused by a single infectious subject in a wholly susceptible population, the above relationship biologically means that if this number is less than or equal to one the disease goes extinct, whereas if this number is greater than one the disease will remain permanently endemic in the population.
=== Cost effectiveness === The costs of methenamine for long-term UTI prophylaxis can be significant. However, a 2024 study found that methenamine was more cost-effective than low-dose prophylactic antibiotics for prevention of UTIs.
Sources: en.wikipedia.org
==== France ==== Pseudoephedrine-containing combination products were available over-the-counter from pharmacies, most commonly with paracetamol, under the brand names "Dolirhume","Actifed Rhyme Jour et Nuit" et al. Products combining pseudoephedrine and ibuprofen or certain antihistamines were also available (e.g. "Rhinadvil"). However, products containing pseudoephedrine as a single ingredient are not sold. In October 2023, the French health department officially warned against the usage of pseudoephedrine for patients with a cold. It also suggested the substance's availability could be restricted in the future, pending its pharmaceutical re-evaluation on EU level. In December 2024, the government announced pseudoephedrine medicines would henceforth only be obtainable with a prescription.
=== Azo dyes (Fast Blue B/BB) === The United Nations Office on Drugs and Crime (UNODC) found the azo dyes Fast Blue B (3,3'-dimethoxybiphenyl-4,4'-bisdiazonium chloride) and Fast Blue BB (4-benzoylamino-2,5-diethoxybenzenediazonium chloride) superior to Duquenois–Levine, and are currently the most recommended reagents used for cannabinoid testing. The dyes, as water-soluble salts, are typically applied during thin layer chromatography. They are extremely sensitive to a variety of cannabinoids, and very specific in reaction. Fast Blue BB is slightly slower than Fast Blue B, but the resulting colors are more vivid and intense. Due to concerns about Fast Blue B being carcinogenic Fast Blue BB is often used instead, although it too is a suspected carcinogen. Other Azo dyes which are suitable for cannabinoid detection, albeit inferior to Fast Blue B/BB, include Corinth V, Blue LGC, Garnet GC (GR), Red AV, Garnet GBO, Bordeaux GP, and Red P.
== Further reading == Robert J. Silva: Fermium, Mendelevium, Nobelium, and Lawrencium, in: Lester R. Morss, Norman M. Edelstein, Jean Fuger (Hrsg.): The Chemistry of the Actinide and Transactinide Elements, Springer, Dordrecht 2006; ISBN 1-4020-3555-1, p. 1621–1651; doi:10.1007/1-4020-3598-5_13. Seaborg, Glenn T. (ed.) (1978) Proceedings of the Symposium Commemorating the 25th Anniversary of Elements 99 and 100, 23 January 1978, Report LBL-7701 Gmelins Handbuch der anorganischen Chemie, System Nr. 71, Transurane: Teil A 1 II, p. 19–20; Teil A 2, p. 47; Teil B 1, p. 84.
11 December – Researchers demonstrate the use of biological-electronic hybrid Organoid Intelligence, 'Brainoware' (see 1 March), for speech recognition. 12 December – Asteroid 319 Leona occults the bright star Betelgeuse for about 12 seconds as viewed on a narrow path from China to Mexico. 13 December Scientists report that the contents of the sample-return mission of the OSIRIS-REx mission to asteroid Bennu revealed organic molecules as well as unknown materials which require more study to have a better idea of their composition and makeup. The smallest known brown dwarf, weighing just three to four times the mass of Jupiter, is discovered in star cluster IC 348 by astronomers using the James Webb Space Telescope.
Sources: en.wikipedia.org
Lymphocyte Lymphocytes, which are the second most common type of white blood cell in adults, are typically small cells with a round, dark nucleus and a thin strip of pale blue cytoplasm. Some lymphocytes are larger and contain a few blue granules. Increased lymphocyte counts (lymphocytosis) can be caused by viral infections and may also occur after splenectomy. Children have higher lymphocyte counts than adults. Chronic lymphocytic leukaemia presents with an elevated lymphocyte count and abnormal lymphocyte morphology, in which the lymphocytes have extremely dense, clumped nuclei and some cells appear smudged on the blood smear. Low lymphocyte counts (lymphopenia) may be seen in infections such as HIV/AIDS, influenza and viral hepatitis, as well as in protein-energy malnutrition, acute illnesses and drug reactions. In response to viral infections (especially infectious mononucleosis), lymphocytes may increase greatly in size, developing unusually shaped nuclei and large amounts of dark blue cytoplasm. Such cells are referred to as reactive or atypical lymphocytes and when present they are either commented on or counted separately from normal lymphocytes in the manual differential.
In optical design jargon, an apodization function is used to purposely change the input intensity profile of an optical system, and it may be a complicated function to tailor the system to certain properties. Usually, it refers to a non-uniform illumination or transmission profile that approaches zero at the edges.
The substrates of this enzyme are (2R,4S)-2,4-diaminopentanoic acid, water, and oxidised nicotinamide adenine dinucleotide (NAD+). Its products are (2R)-2-amino-4-oxopentanoic acid, reduced NADH, ammonia, and a proton. Nicotinamide adenine dinucleotide phosphate can be used as an alternative cofactor. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-NH2 group of donors with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is 2,4-diaminopentanoate:NAD(P)+ oxidoreductase (deaminating). This enzyme is also called 2,4-diaminopentanoic acid C4 dehydrogenase. This enzyme participates in 3 metabolic pathways: lysine degradation, arginine and proline metabolism, and d-arginine and d-ornithine metabolism.
Sources: en.wikipedia.org
As of the mid-2020s retatrutide remains investigational and is not an approved medicine in the United States or the European Union. It has been supplied mainly to participants in clinical trials. Labels and availability can change, so regulatory listings should be checked directly.
Dual agonists act at the GLP-1 and GIP receptors, whereas retatrutide adds glucagon receptor activity on the same peptide. This third activity is the main structural and pharmacological distinction discussed in the literature. Direct head-to-head comparisons remain limited.
Reports usually give the study code LY3437943 alongside the name, the dose in milligrams, and the week at which an endpoint was measured. Percent body-weight change is the most frequent headline measure. Units and populations vary, so comparisons across reports require care.
Retatrutide is an investigational peptide that activates the GLP-1, GIP, and glucagon receptors at the same time. It is being studied for obesity and type 2 diabetes and has not been approved for clinical use. The internal code LY3437943 refers to the same molecule.